Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Aromatase inhibition to enhance assisted reproduction
An aromatase inhibitor, assisted reproductive technology, applied in aromatase inhibitors, improving women's follicle production, pharmaceutical preparations and related applications, can solve the problem of no dominant follicles
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0402] This embodiment is a prospective controlled study, including 1 study group and 1 control group. The patients in the study group received letrozole (2.5 mg per day from the 3rd day to the 7th day of menstrual period) and FSH. Group received only FSH. The study group included 12 patients with unexplained infertility. The control group consisted of 55 patients with unexplained infertility. All patients received recombinant or highly purified FSH (50-150 IU daily from day 3 to day 7 until the day when hCG (10,000 IU) was given when 2 main follicles were larger than 2 cm). The FSH treatment regimen is based on the patient's clinical condition. Patients are not arbitrary. All patients underwent artificial insemination. There were no statistically significant differences between the study and control groups in age, weight, duration of infertility, number of prior fertilization cycles, semen volume, or type of FSH.
[0403] Table 1
[0404] NS means no meaning...
Embodiment 2
[0406] Fifteen patients were selected, who were given clomiphene citrate (CC) and did not ovulate (6 cycles), or ovulated but the endometrial thickness was less than 5 mm (24 cycles) and could not conceive. They were given letrozole orally at a dose of 2.5 to 5 mg daily from days 3 to 7 or days 5 to 9 of the menstrual period for at least 2 months after the cycle. Ovulation induction was given with 10,000 IU hCG. CC was given at 50-100 mg per dose on days 3-7 or 5-9.
[0407] Table 2
average
scope
median value
treatment solutions
Letrozole
CC
P value
Letrozole
CC
Letrozole
CC
Days of hCG administration
Day 14.5
Day 12.6
S
11th-18th
day
11th-16th
day
day 15
day 12
Give the last letrozole tablet to
Number of days between days when hCG was administered
6.7
4.4
S
2-9
2-7
7
...
Embodiment 3
[0411] table 3
PUM
| Property | Measurement | Unit |
|---|---|---|
| thickness | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More - R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com